meRfi®-GM
Talazoparib & Breast Cancer / Mammacarcinoma (BRCA m)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
On October 16, 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib for patients with deleterious or suspected deleterious germline BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib.
Talazoparib was associated with superior efficacy, favorable patient-reported outcomes (PROs), and lower health resource utilization (HRU) rate versus chemotherapy in advanced Breast Cancer / Mammacarcinoma (BRCA m). Toxicities were manageable with talazoparib dose modification and supportive care.
see also:
[PARPs (Poly(ADP-Ribose) Polymerases) Inhibitors & Breast Cancer / Mammac…
References (Sources)
- Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib
- NCT03499353 - Talazoparib - Early Breast Cancer
- Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
- Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation